Morten Munk

Morten Munk has over 30 years of industry experience in biopharmaceutical development and manufacturing and is a globally recognized technical expert in the field. He has authored or co-authored a number of technical articles and guidelines. Morten Munk joined NNE in 2015 as Global Technology Partner, supporting all aspects around biopharmaceutical development and manufacturing.

In 2001 Morten co-founded CMC Biologics A/S, where he held a position as Vice President for Business Development. Prior to founding CMC Biologics, Morten held a position as principal scientist at Novo Nordisk A/S in which he was responsible for the CMC part of several projects, which have been commercialized successfully, including development of the slow acting insulin analogue, named Levemir / Detemir.